FOLH1 and myeloid sarcoma: This targeting is relevant as both GCPII and NAAG are known to be measurably upregulated in activated microglia 24, 25, making dendrimers a potentially efficacious GCPII inhibitor delivery vehicle for the treatment of cognitive impairment in MS.